Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New phase I trial methodology

S Mani1, M J Ratain

  • 1Department of Medicine, University of Chicago, IL 60637-1470, USA.

Seminars in Oncology
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Phase I trial design is evolving for safer, faster dose escalation. New strategies accommodate targeted therapies, aiming for timely completion of early-phase cancer drug studies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Hormonal stimulation reduces numbers and impairs function of human uterine natural killer cells during implantation.

Human reproduction (Oxford, England)·2023
Same author

Potential antiviral effects of pantethine against SARS-CoV-2.

Scientific reports·2023
Same author

Urinary Ascites and Transient Intestinal Obstruction in a Preterm Infant: An Interesting Case of Posterior Urethral Valve.

AJP reports·2019
Same author

<i>REPLY</i>.

AJNR. American journal of neuroradiology·2018
Same author

Brain Imaging in Cases with Positive Serology for Dengue with Neurologic Symptoms: A Clinicoradiologic Correlation.

AJNR. American journal of neuroradiology·2018
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Drug Development

Background:

  • Traditional Phase I trial designs face limitations.
  • There is a growing need for efficient dose escalation methods.
  • Rationally designed agents, including pathway-specific inhibitors, are increasingly prevalent.

Purpose of the Study:

  • To discuss key aspects of Phase I trial design.
  • To explore novel, safer, and rapid dose escalation strategies.
  • To address trial design considerations for rationally designed agents.

Main Methods:

  • Review of current Phase I trial design principles.
  • Discussion of dose escalation methodologies.
  • Exploration of strategies for targeted therapy trials.

Related Experiment Videos

Main Results:

  • Phase I trial design requires continuous adaptation.
  • Identifying reproducible endpoints like maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) is crucial.
  • Newer agents necessitate tailored trial designs.

Conclusions:

  • Evolving Phase I trial designs are essential for modern drug development.
  • Integrating innovative dose titration with existing methods can accelerate trials.
  • Future strategies should optimize early-phase trial efficiency for targeted therapies.